SREBF1 and fatty liver disease: In this study, compound C significantly reduces hepatic steatosis and reduces the activity of the lipogenic genes, including peroxisome proliferator‐activated receptor gamma (PPARγ), fatty acid synthase (FAS), and sterol regulatory element-binding protein 1c (SREBP1c), which are critical transcriptional regulators for the target genes involved in lipid synthesis [16].